The Foster City-based drug developer (NASDAQ: GILD), known mainly for its drug that fight the AIDS virus, saw its stock rise nearly 10 percent by mid-day Friday after saying on Thursday that a combination of oral PSI-7977 and the anti-viral drug ribavirin cured a group of hepatitis C patients after just four weeks of therapy.
Gilead Chief Scientific Officer Norbert Bischofberger told analysts that the patients with genotype 1 hepatitis C had no detectable signs of the virus.
No comments:
Post a Comment